Federico Soriguer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Federico Soriguer has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Gemma Rojo-Martínez
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain
5 shared publications - Elehazara Rubio-Martín
Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Malaga, Spain
3 shared publications - Gabriel Olveira
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain
3 shared publications - Eva García-Escobar
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain
2 shared publications - María Soledad Ruiz de Adana
Diabetes Unit, Endocrinology and Nutrition Service, Regional University Hospital of Málaga, IBIMA/BIONAD, Ciberdem, 29010 Malaga, Spain
2 shared publications - Sergio Valdés
Ciber
2 shared publications
Latest Publications
- Open Access
- 27 September 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (19) , 10417
Epigenetic Biomarkers of Transition from Metabolically Healthy Obesity to Metabolically Unhealthy Obesity Phenotype: A Prospective Study
Background: Identifying those parameters that could potentially predict the deterioration of metabolically healthy phenotype is a matter of debate. In this field, epigenetics, in particular DNA methylation deserves special attention. Results: The aim of the present study was to analyze the long-term evolution of methylation patterns in a subset of metabolically healthy subjects in order to search for epigenetic markers that could predict the progression to an unhealthy state. Twenty-six CpG sites were significantly differentially methylated, both at baseline and 11-year follow-up. These sites were related to 19 genes or pseudogenes; a more in-depth analysis of the methylation sites of these genes showed that CYP2E1 had 50% of the collected CpG sites differently methylated between stable metabolically healthy obesity (MHO) and unstable MHO, followed by HLA-DRB1 (33%), ZBTB45 (16%), HOOK3 (14%), PLCZ1 (14%), SLC1A1 (12%), MUC2 (12%), ZFPM2 (12.5%) and HLA-DQB2 (8%). Pathway analysis of the selected 26 CpG sites showed enrichment in pathways linked to th1 and th2 activation, antigen presentation, allograft rejection signals and metabolic processes. Higher methylation levels in the cg20707527 (ZFPM2) could have a protective effect against the progression to unstable MHO (OR: 0.21, 95%CI (0.067–0.667), p < 0.0001), whilst higher methylation levels in cg11445109 (CYP2E1) would increase the progression to MUO; OR: 2.72, 95%CI (1.094–6.796), p < 0.0014; respectively). Conclusions: DNA methylation status is associated with the stability/worsening of MHO phenotype. Two potential biomarkers of the transition to an unhealthy state were identified and deserve further investigation (cg20707527 and cg11445109). Moreover, the described differences in methylation could alter immune system-related pathways, highlighting these pathways as therapeutic targets to prevent metabolic deterioration in MHO patients.
- 27 September 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (19) , 10417
Open AccessEpigenetic Biomarkers of Transition from Metabolically Healthy Obesity to Metabolically Unhealthy Obesity Phenotype: A Prospective Study
Background: Identifying those parameters that could potentially predict the deterioration of metabolically healthy phenotype is a matter of debate. In this field, epigenetics, in particular DNA methylation deserves special attention. Results: The aim of the present study was to analyze the long-term evolution of methylation patterns in a subset of metabolically healthy subjects in order to search for epigenetic markers that could predict the progression to an unhealthy state. Twenty-six CpG sites were significantly differentially methylated, both at baseline and 11-year follow-up. These sites were related to 19 genes or pseudogenes; a more in-depth analysis of the methylation sites of these genes showed that CYP2E1 had 50% of the collected CpG sites differently methylated between stable metabolically healthy obesity (MHO) and unstable MHO, followed by HLA-DRB1 (33%), ZBTB45 (16%), HOOK3 (14%), PLCZ1 (14%), SLC1A1 (12%), MUC2 (12%), ZFPM2 (12.5%) and HLA-DQB2 (8%). Pathway analysis of the selected 26 CpG sites showed enrichment in pathways linked to th1 and th2 activation, antigen presentation, allograft rejection signals and metabolic processes. Higher methylation levels in the cg20707527 (ZFPM2) could have a protective effect against the progression to unstable MHO (OR: 0.21, 95%CI (0.067–0.667), p < 0.0001), whilst higher methylation levels in cg11445109 (CYP2E1) would increase the progression to MUO; OR: 2.72, 95%CI (1.094–6.796), p < 0.0014; respectively). Conclusions: DNA methylation status is associated with the stability/worsening of MHO phenotype. Two potential biomarkers of the transition to an unhealthy state were identified and deserve further investigation (cg20707527 and cg11445109). Moreover, the described differences in methylation could alter immune system-related pathways, highlighting these pathways as therapeutic targets to prevent metabolic deterioration in MHO patients.
- Open Access
Dairy Product Consumption and Metabolic Diseases in the Di@bet.es Study
To date it is not clear what the role of dairy products is in metabolic diseases like diabetes, obesity, and hypertension. Therefore, the aim of this study is to test the association between dairy product consumption and those pathologies. A cross-sectional study was conducted with 5081 adults included in the di@bet.es study, from 100 health centers around Spain. Food frequency questionnaires were carried out concerning consumption habits, which included dairy product consumption. Logistic regression models were used for the association analyses between the variables controlling confounding variables. Women had a higher consumption of milk, cheese, or yogurt than men (p < 0.0001), but men consumed more sugar dairy products (p < 0.001). People who live in the North of Spain consume more dairy products than those who live in the East. Dairy product consumption was inversely associated with the presence of hypertension regardless of age, sex, geographical region, and body mass index (BMI) (Odds Ratio (OR) 0.743; p = 0.022). The presence of obesity was inversely associated with dairy consumption regardless of age, sex, and geographical region (OR 0.61; p < 0.001). Milk consumption was not associated with diabetes. Our results show that consuming dairy products is associated with a better metabolic profile in the Spanish population.
Open AccessDairy Product Consumption and Metabolic Diseases in the Di@bet.es Study
To date it is not clear what the role of dairy products is in metabolic diseases like diabetes, obesity, and hypertension. Therefore, the aim of this study is to test the association between dairy product consumption and those pathologies. A cross-sectional study was conducted with 5081 adults included in the di@bet.es study, from 100 health centers around Spain. Food frequency questionnaires were carried out concerning consumption habits, which included dairy product consumption. Logistic regression models were used for the association analyses between the variables controlling confounding variables. Women had a higher consumption of milk, cheese, or yogurt than men (p < 0.0001), but men consumed more sugar dairy products (p < 0.001). People who live in the North of Spain consume more dairy products than those who live in the East. Dairy product consumption was inversely associated with the presence of hypertension regardless of age, sex, geographical region, and body mass index (BMI) (Odds Ratio (OR) 0.743; p = 0.022). The presence of obesity was inversely associated with dairy consumption regardless of age, sex, and geographical region (OR 0.61; p < 0.001). Milk consumption was not associated with diabetes. Our results show that consuming dairy products is associated with a better metabolic profile in the Spanish population.
- Open Access
Comparison of the Effects of Goat Dairy and Cow Dairy Based Breakfasts on Satiety, Appetite Hormones, and Metabolic Profile
The satiating effects of cow dairy have been thoroughly investigated; however, the effects of goat dairy on appetite have not been reported so far. Our study investigates the satiating effect of two breakfasts based on goat or cow dairy and their association with appetite related hormones and metabolic profile. Healthy adults consumed two breakfasts based on goat (G-Breakfast) or cow (C-Breakfast) dairy products. Blood samples were taken and VAS tests were performed at different time points. Blood metabolites were measured and Combined Satiety Index (CSI) and areas under the curves (AUC) were calculated. Desire to eat rating was significantly lower (breakfast & time interaction p < 0.01) and hunger rating tended to be lower (breakfast & time interaction p = 0.06) after the G-breakfast. None of the blood parameters studied were different between breakfasts; however, AUCGLP-1 was inversely associated with the AUChunger and AUCdesire-to-eat after the G-Breakfast, whereas triglyceride levels were directly associated with AUCCSI after the C-Breakfast. Our results suggest a slightly higher satiating effect of goat dairy when compared to cow dairy products, and pointed to a potential association of GLP-1 and triglyceride levels with the mechanisms by which dairy products might affect satiety after the G-Breakfast and C-Breakfast, respectively.
Open AccessComparison of the Effects of Goat Dairy and Cow Dairy Based Breakfasts on Satiety, Appetite Hormones, and Metabolic Profile
The satiating effects of cow dairy have been thoroughly investigated; however, the effects of goat dairy on appetite have not been reported so far. Our study investigates the satiating effect of two breakfasts based on goat or cow dairy and their association with appetite related hormones and metabolic profile. Healthy adults consumed two breakfasts based on goat (G-Breakfast) or cow (C-Breakfast) dairy products. Blood samples were taken and VAS tests were performed at different time points. Blood metabolites were measured and Combined Satiety Index (CSI) and areas under the curves (AUC) were calculated. Desire to eat rating was significantly lower (breakfast & time interaction p < 0.01) and hunger rating tended to be lower (breakfast & time interaction p = 0.06) after the G-breakfast. None of the blood parameters studied were different between breakfasts; however, AUCGLP-1 was inversely associated with the AUChunger and AUCdesire-to-eat after the G-Breakfast, whereas triglyceride levels were directly associated with AUCCSI after the C-Breakfast. Our results suggest a slightly higher satiating effect of goat dairy when compared to cow dairy products, and pointed to a potential association of GLP-1 and triglyceride levels with the mechanisms by which dairy products might affect satiety after the G-Breakfast and C-Breakfast, respectively.
- Open Access
- 29 November 2016
- Published by ARAN Ediciones in Nutrición Hospitalaria
- Vol. 33 (6) , 1257-1259
¿Estamos dando los españoles la talla?
Desde hace algún tiempo sabemos que la talla de las poblaciones es un buen instrumento para analizar la evolución socioeconómica, habiendo dejado de ser motivo de estudio solo por la biomedicina para serlo también por los economistas y sociólogos. Es lo que han hecho Martínez Carrión y cols., con el trabajo que aparece en este número de Nutrición Hospitalaria.
- 29 November 2016
- Published by ARAN Ediciones in Nutrición Hospitalaria
- Vol. 33 (6) , 1257-1259
Open Access¿Estamos dando los españoles la talla?
Desde hace algún tiempo sabemos que la talla de las poblaciones es un buen instrumento para analizar la evolución socioeconómica, habiendo dejado de ser motivo de estudio solo por la biomedicina para serlo también por los economistas y sociólogos. Es lo que han hecho Martínez Carrión y cols., con el trabajo que aparece en este número de Nutrición Hospitalaria.
- 1 October 2015
- Vol. 32 (4) , 1766-1772
SATISFACCIÓN CON EL MENÚ HOSPITALARIO E INCORPORACIÓN DEL QUESO DE
The evaluation of hospital menus should be performed periodically to suit the needs of patients. Goat cheese may have nutritional benefits, compared to cow cheese. to evaluate patient satisfaction with the hospital menu and with the inclusion of goat cheese, given like dessert in hospital vs menu with cow cheese. a survey of hospital menu satisfaction and dessert (goat cheese (GC) vs cow cheese (CC)) in patients with basal diets was conducted. 334 surveys were analyzed. 46.7% were women. The average age was 58.16 ± 15.15 years and the average stay of 11.21 ± 11.53. Acceptance of the hospital menu was rated as "good" in a high percentage of respondents (91% Temperature, presentation 94%, humidity 75% and 84% schedule). Overall satisfaction lunch (1 to 10) was 7.31 ± 2.10 en CC vs 7.39 ± 1.75 GC (ns) and dessert satisfaction was 6.93 ± 2.89 vs 6.88 ± 3.52 (ns) (respectively). the overall satisfaction with the hospital menu is high and the acceptance of new dessert (QC) is equivalent to acceptance obtained with cow cheese, which could be included in the code of diets.
- 1 October 2015
- Vol. 32 (4) , 1766-1772
SATISFACCIÓN CON EL MENÚ HOSPITALARIO E INCORPORACIÓN DEL QUESO DE
The evaluation of hospital menus should be performed periodically to suit the needs of patients. Goat cheese may have nutritional benefits, compared to cow cheese. to evaluate patient satisfaction with the hospital menu and with the inclusion of goat cheese, given like dessert in hospital vs menu with cow cheese. a survey of hospital menu satisfaction and dessert (goat cheese (GC) vs cow cheese (CC)) in patients with basal diets was conducted. 334 surveys were analyzed. 46.7% were women. The average age was 58.16 ± 15.15 years and the average stay of 11.21 ± 11.53. Acceptance of the hospital menu was rated as "good" in a high percentage of respondents (91% Temperature, presentation 94%, humidity 75% and 84% schedule). Overall satisfaction lunch (1 to 10) was 7.31 ± 2.10 en CC vs 7.39 ± 1.75 GC (ns) and dessert satisfaction was 6.93 ± 2.89 vs 6.88 ± 3.52 (ns) (respectively). the overall satisfaction with the hospital menu is high and the acceptance of new dessert (QC) is equivalent to acceptance obtained with cow cheese, which could be included in the code of diets.
- 1 November 2014
- Published by Elsevier in Revista Clínica Española
- Vol. 214 (8) , 453-454
Control glucémico en pacientes con diabetes mellitus tipo 2 en España: ¿Quo vadis?
- 1 November 2014
- Published by Elsevier in Revista Clínica Española
- Vol. 214 (8) , 453-454
Control glucémico en pacientes con diabetes mellitus tipo 2 en España: ¿Quo vadis?
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
Clinical usefulness of a bolus calculator in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion (CSII)
Objective: One of the major problems related to the use of CSII, or intensive insulin regimens in general, is the calculation of accurate insulin boluses. Abolus calculator incorporated into the insulin pump, estimates the dose of insulin to be administered at the meal on the basis of the following parameters: current blood glucose, grams of carbohydrate in the meal, carbohydrate to-insulin ratio (CIR), insulin sensitivity factors (ISF), target blood glucose and quantity of insulin previously administered, hereby making calculation easier and more precise. The aim of the present study was to assess the efficacy of a bolus calculator incorporated into the insulin pump on pre and postprandial glycaemic control of patients with type 1 diabetes on continuous s.c. insulin infusion, evaluating changes in insulin dose, number of boluses administered, acute complications, glycemic variability and HbA1c, and quality of life. Material y methods: We enrolled 20 subjects (8 men/12 women) older than 18 years old (mean age: 36±12 years) with type 1 diabetes patients treated for more than 12 months (time on insulin pump therapy: 50±32 months) with continuous s.c. insulin infusion (Minimed 722, Medtronic). The patients received a infrared-linked glucometer (Contour Bayer) so that glycemic values were directly transmitted to the pump to be used by the bolus calculator, with possibility to download all the recorded data. We calculate basal CIR and ISF for all the patients, who received all the information for the accurate use of the bolus calculator. The following data were evaluated baseline and after 3 months using the bolus calculator: HbA1c, daily insulin dose(Basal and bolus), number of bolus/day, acute complications. Glycemiclability was evaluated using MAGE and S.D. from SMBG information, and quality of life (DQOL). A treatment satisfaction questionnaire was also evaluated. Results: After 3 months using the bolus calculator we observed significant changes (P< 0.05) in weight (71.8±8 vs 72.9 kg)and methabolic control (HbA1C 7.7±1.1 vs 7.5±1%), we did not find differences in SMBG downloaded data (time in normo, hypo and hyperglucemia), S.D., MAGE, insulin daily dose, basal/bolus distribution, number of boluses/day, and DQOL. Patients were satisfied with the bolus calculator, they find this option easy to use and accurate. Conclusions: In a group of patients treated with continuous s.c. insulin infusion the addition of the use of a bolus calculator achieved an improvement in glycemic control with decrease of HbA1c levels, without changes in other studied parameters, with a high level of satisfaction of the patients.
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
Clinical usefulness of a bolus calculator in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion (CSII)
Objective: One of the major problems related to the use of CSII, or intensive insulin regimens in general, is the calculation of accurate insulin boluses. Abolus calculator incorporated into the insulin pump, estimates the dose of insulin to be administered at the meal on the basis of the following parameters: current blood glucose, grams of carbohydrate in the meal, carbohydrate to-insulin ratio (CIR), insulin sensitivity factors (ISF), target blood glucose and quantity of insulin previously administered, hereby making calculation easier and more precise. The aim of the present study was to assess the efficacy of a bolus calculator incorporated into the insulin pump on pre and postprandial glycaemic control of patients with type 1 diabetes on continuous s.c. insulin infusion, evaluating changes in insulin dose, number of boluses administered, acute complications, glycemic variability and HbA1c, and quality of life. Material y methods: We enrolled 20 subjects (8 men/12 women) older than 18 years old (mean age: 36±12 years) with type 1 diabetes patients treated for more than 12 months (time on insulin pump therapy: 50±32 months) with continuous s.c. insulin infusion (Minimed 722, Medtronic). The patients received a infrared-linked glucometer (Contour Bayer) so that glycemic values were directly transmitted to the pump to be used by the bolus calculator, with possibility to download all the recorded data. We calculate basal CIR and ISF for all the patients, who received all the information for the accurate use of the bolus calculator. The following data were evaluated baseline and after 3 months using the bolus calculator: HbA1c, daily insulin dose(Basal and bolus), number of bolus/day, acute complications. Glycemiclability was evaluated using MAGE and S.D. from SMBG information, and quality of life (DQOL). A treatment satisfaction questionnaire was also evaluated. Results: After 3 months using the bolus calculator we observed significant changes (P< 0.05) in weight (71.8±8 vs 72.9 kg)and methabolic control (HbA1C 7.7±1.1 vs 7.5±1%), we did not find differences in SMBG downloaded data (time in normo, hypo and hyperglucemia), S.D., MAGE, insulin daily dose, basal/bolus distribution, number of boluses/day, and DQOL. Patients were satisfied with the bolus calculator, they find this option easy to use and accurate. Conclusions: In a group of patients treated with continuous s.c. insulin infusion the addition of the use of a bolus calculator achieved an improvement in glycemic control with decrease of HbA1c levels, without changes in other studied parameters, with a high level of satisfaction of the patients.
- 1 March 2012
- Published by Elsevier in Avances en Diabetología
- Vol. 28 (2) , 35-37
El estudio Di@bet.es, ¿y ahora qué?
- 1 March 2012
- Published by Elsevier in Avances en Diabetología
- Vol. 28 (2) , 35-37
El estudio Di@bet.es, ¿y ahora qué?
- 12 September 2011
- Published by American Psychological Association (APA)
Fear of Hypoglycemia Scale